RUNX1-RUNX1T1 AML1-ETO t8;21 Qualitative Test
Cost: 900.0 AED
Symptoms, Diagnosis, and Test Details
The RUNX1-RUNX1T1 gene fusion, also known as AML1-ETO, is a genetic abnormality commonly found in acute myeloid leukemia (AML) patients. It results from a translocation between chromosomes 8 and 21, specifically the t(8;21) translocation. Qualitative testing refers to a diagnostic method that determines the presence or absence of a specific genetic alteration.
In the case of t(8;21), qualitative testing would confirm whether the RUNX1-RUNX1T1 fusion gene is present in a patient’s leukemia cells. This testing can be performed using various molecular techniques, such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH). These methods detect the fusion gene’s specific DNA sequence or the physical location of the translocation, respectively.
Qualitative testing for t(8;21) is important for diagnosing AML and determining appropriate treatment options. The presence of this fusion gene is associated with a favorable prognosis, and patients with t(8;21) AML may respond well to certain chemotherapy regimens.
Test Components
- EDTA Vacutainer (2ml)
Sample Condition
Bone marrow / Peripheral blood (Transport immediately)
Report Delivery
3-4 days
Method
Real Time PCR
Test Type
Genetics
Doctor
General Physician
Test Department
Pre Test Information
RUNX1-RUNX1T1 (AML1-ETO) t(8;21) Qualitative can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.
| Test Name | RUNX1-RUNX1T1 AML1- ETO t8;21 Qualitative Test |
|---|---|
| Components | EDTA Vacutainer (2ml) |
| Price | 900.0 AED |
| Sample Condition | Bone marrow \/ Peripheral blood (Transport immediately) |
| Report Delivery | 3-4 days |
| Method | Real Time PCR |
| Test type | Genetics |
| Doctor | General Physician |
| Test Department: | |
| Pre Test Information | RUNX1-RUNX1T1 (AML1- ETO) t(8;21) Qualitative can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad. |
| Test Details |
The RUNX1-RUNX1T1 gene fusion, also known as AML1-ETO, is a genetic abnormality commonly found in acute myeloid leukemia (AML) patients. It results from a translocation between chromosomes 8 and 21, specifically the t(8;21) translocation. Qualitative testing refers to a diagnostic method that determines the presence or absence of a specific genetic alteration. In the case of t(8;21), qualitative testing would confirm whether the RUNX1-RUNX1T1 fusion gene is present in a patient’s leukemia cells. This testing can be performed using various molecular techniques, such as polymerase chain reaction (PCR) or fluorescence in situ hybridization (FISH). These methods detect the fusion gene’s specific DNA sequence or the physical location of the translocation, respectively. Qualitative testing for t(8;21) is important for diagnosing AML and determining appropriate treatment options. The presence of this fusion gene is associated with a favorable prognosis, and patients with t(8;21) AML may respond well to certain chemotherapy regimens. |
